GlobeNewswire Inc | Mar 9, 2021 08:00AM EST

March 09, 2021

CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today it will host a conference call and webcast to provide a business update onTuesday, March 16, 2021at4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Companyswebsite.

Members of theCue Biopharmaexecutive management team will provide clinical updates on the Companys ongoing CUE-101 Phase 1 dose escalation monotherapy trial, which will include new patient data, and on the combination trial KEYNOTE-A78, where CUE-101 will be evaluated in combination with KEYTRUDA (pembrolizumab) as first-line treatment for HPV+ recurrent/metastatic head and neck squamous cell carcinoma. Management will also provide an update on the Companys most recent technology platform developments and pipeline progress as well as updates on its strategic objectives and anticipated milestones.

Tuesday, March 16 at4:30 p.m. EDT

Investors: 877-407-9208International: 201-493-6784Conference ID: 13716744Webcast: http://public.viavid.com/index.php?id=143645

AboutCue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patients body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The companys proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visitwww.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.

Investor ContactGeorge B. Zavoico, Ph.D.VP, Investor Relations & Corporate Development Cue Biopharma, Inc. gzavoico@cuebio.com

Media ContactDarren Opland, Ph.D.LifeSci Communicationsdarren@lifescicomms.com